GAMG

Derived from the biopsy specimen of a 42-year-old female patient with histologically confirmed glioblastoma, GaMG (also designated GaMg or GAMG) is a hypotriploid human cell line that retains key genotypic and phenotypic hallmarks of primary glioblastoma. Its provenance and characterized karyotypic features-including polyploidy, double minutes (dm), and structural rearrangements-position it as a biologically faithful surrogate for the aggressive, genetically unstable nature of de novo GBM.

1. Validated Hypoxia-Responsive Phenotype: GaMG demonstrates robust, inducible expression of HIF-1α and downstream targets (e.g., NDRG1) under low oxygen tension, faithfully recapitulating the pseudohypoxic signaling axis central to GBM chemoresistance and invasion. This renders it a preferred system for interrogating oxygen-dependent transcriptional programs and validating hypoxia-targeted interventions.
2. Reference Caliber for Molecular Normalization: Critically, GaMG exhibits stable GAPDH expression refractory to hypoxic regulation. This attribute establishes it as a gold-standard reference for quantitative PCR and Western blot normalization in GBM research, eliminating a common confounder in tumor microenvironment studies.
3. Translational Relevance for Pharmacogenomics: Beyond hypoxia biology, GaMG responds transcriptionally to clinically approved psychotropic and chemotherapeutic agents via LXR/SREBP pathways, providing a human-relevant platform to study drug-induced lipid metabolism, off-target toxicities, and adjuvant repurposing.

These characteristics establish GaMG not merely as another glioblastoma line, but as a clinically annotated, physiologically responsive tool optimized for hypoxia signaling, reference-standard normalization, and mechanism-driven neuro-oncology discovery.